echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Saisheng Pharmaceutical's Small Molecule Conjugate Drug Application for Clinical Application

    Saisheng Pharmaceutical's Small Molecule Conjugate Drug Application for Clinical Application

    • Last Update: 2022-05-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Cube Info

    Author: Pickup

    On April 7, the CDE official website showed that the clinical application of PEN-866 sodium for injection by Saisheng Pharmaceutical was accepted by the State Food and Drug Administration


    PEN-866 is a small molecule drug conjugate (SMDC) developed by Saison Pharmaceuticals and is currently conducting a Phase II basket trial for solid tumors in the United States


    Antibody drug conjugates (ADCs) are undoubtedly the most concerned representatives of drug conjugates nowadays, and the therapeutic breakthroughs and transactions of listed and clinical drugs have also attracted much attention; however, the defects of ADC drugs are also obvious, such as the inability to target intracellular proteins, Complex production processes and regulatory challenges,


    Different from ADC, SMDC achieves targeted localization through small molecules and precise drug release, which is also a potential branch in the drug conjugate track


    PEN-866 structure

    Importantly, SMDC has similar advantages to ADC in clinical manifestations, especially the control of adverse reactions


    Clinical data showed that no DLT (dose limiting toxicity) was observed with PEN-866 at the recommended dose (175 mg/m2), and only 1 patient experienced uncomplicated grade G3 transient neutropenia , compared with irinotecan up to 53.


    PEN-866 was originally developed by Tarveda.


    It is reported that the companies currently deploying small molecule conjugated drugs in China include Tongyi Medicine (CBP-1008, CBP-1018), Institute of Basic Medicine, Chinese Academy of Medical Sciences (DTX-P7), Saisheng Pharmaceutical (PEN-866, T- 2143), Taiwan Haoding Biotechnology (OBI-3424)


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.